Migraine is far more than a headache — the nausea, vomiting, and gastric stasis that accompany attacks are driven by vagal pathways, and vagus nerve stimulation is now an FDA-cleared treatment option. The vagus nerve sits at the intersection of migraine’s pain signalling, its autonomic symptoms, and one of its most promising non-drug therapies.
Why Migraines Involve the Vagus Nerve
The nausea and vomiting experienced by 60–80% of migraine sufferers aren’t incidental — they reflect direct vagal involvement. During a migraine attack, activation of the trigeminovascular system cross-activates vagal afferents through convergent projections in the nucleus tractus solitarius (NTS). The NTS connects to the dorsal motor nucleus of the vagus, which controls gastric motility. This trigeminovagal reflex produces the gastroparesis (stomach paralysis) that occurs during migraines, explaining why oral medications are poorly absorbed during attacks and why patients often feel bloated or unable to eat.
Calcitonin gene-related peptide (CGRP) — the molecule now targeted by the newest migraine drug class — is released by trigeminal nerve endings during attacks. CGRP also activates vagal afferents, contributing to the nausea response and creating a feedback loop between trigeminal pain signalling and vagal symptoms. This is why CGRP-blocking medications (erenumab, fremanezumab, galcanezumab) reduce nausea alongside headache.
The vagus nerve also carries information about head and neck blood vessel changes to the brainstem. During the aura phase, cortical spreading depression activates meningeal nociceptors that signal through both trigeminal and vagal afferents, contributing to the autonomic prodromal symptoms — yawning, fatigue, food cravings — that many patients recognise hours before pain begins.
gammaCore: Non-Invasive Vagus Nerve Stimulation for Migraine
gammaCore is a handheld device that delivers non-invasive vagus nerve stimulation (nVNS) through the skin of the neck over the cervical vagus nerve. It received FDA clearance for acute migraine treatment in 2018 and for prevention of migraine and cluster headache.
The key clinical trials supporting gammaCore include the PRESTO trial, which demonstrated that nVNS provided pain freedom at two hours significantly more often than sham stimulation for acute episodic migraine. The ACT1 and ACT2 trials established efficacy for acute treatment of episodic cluster headache, with a notable subgroup analysis showing stronger benefit in episodic versus chronic cluster headache.
The Sapphire 2024 update provided longer-term real-world effectiveness data, confirming that patients who respond to gammaCore tend to maintain benefit with continued use. However, response rates are moderate — not every patient benefits, and effect sizes are smaller than those seen with triptans for acute treatment. gammaCore’s advantage is its favourable side-effect profile (no medication overuse headache risk, no cardiovascular contraindications) and the ability to use it alongside existing treatments.
The device is applied to one side of the neck for 120 seconds per stimulation, with treatment typically involving two or three consecutive stimulations at the onset of a migraine. For prevention, patients use a set number of stimulations daily regardless of symptoms.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
How Vagus Nerve Stimulation Works Against Migraine
The proposed mechanisms for nVNS in migraine involve several pathways. Vagal afferent stimulation activates the NTS, which projects to the locus coeruleus, releasing norepinephrine that modulates pain processing in the trigeminal nucleus caudalis. This effectively raises the threshold for trigeminovascular activation.
nVNS also appears to reduce cortical excitability, potentially suppressing the cortical spreading depression that underlies migraine aura. Animal studies have shown that vagus nerve stimulation reduces CGRP release from trigeminal neurons and dampens neurogenic inflammation in the meninges — the same targets that CGRP antibodies hit, but through a neurological rather than pharmacological mechanism.
Additionally, vagal stimulation activates descending pain inhibition pathways through the periaqueductal grey and rostral ventromedial medulla — brainstem structures that gate pain signals before they reach conscious awareness. This top-down pain modulation explains why some patients report benefit even when nVNS is applied after pain has fully established.
Other Vagal Approaches to Migraine
Auricular transcutaneous VNS (taVNS), which targets the auricular branch of the vagus nerve in the ear, has been investigated for migraine prevention with mixed results. While the JAMA Network Open 2024 trial showed strong results for taVNS in insomnia, the migraine-specific evidence is less robust than for cervical nVNS via gammaCore. Some small trials show promise, but larger confirmatory studies are needed.
Breathing techniques during the migraine prodrome have physiological plausibility — slow breathing enhances vagal tone and may help regulate the autonomic instability that precedes attacks. The Stanford 2023 physiological sigh study (Cell Reports Medicine) showed that structured breathing outperformed meditation for acute stress reduction, though this wasn’t tested specifically in migraine patients.
Cold face immersion, which activates the mammalian diving reflex through the trigeminal nerve (separate from vagal cold receptors), has anecdotal support from some migraine patients for acute symptom relief. The diving reflex produces strong parasympathetic activation and may counteract the sympathetic surge that accompanies severe migraine pain, but no controlled trials have tested this specifically.
What the Evidence Actually Supports
For patients interested in vagal approaches to migraine, the evidence hierarchy is clear. gammaCore has the strongest clinical trial support and FDA clearance, making it the most evidence-based vagal option. It works best as an add-on therapy — the data doesn’t support replacing proven treatments (triptans, CGRP antibodies, preventive medications) with nVNS alone.
Implanted VNS, originally developed for epilepsy, has shown migraine reduction as a secondary finding in epilepsy patients, but the invasiveness and cost aren’t justified for migraine alone given that non-invasive alternatives exist.
Regular aerobic exercise — which improves vagal tone over time — has consistent evidence for migraine prevention, with studies showing frequency reductions comparable to some preventive medications. This represents the most accessible vagal intervention for migraine, requiring no devices or prescriptions.
The vagus nerve’s role in migraine is genuine and increasingly well-characterised, but it’s one component of a complex neurological condition. The most effective migraine management typically combines multiple approaches rather than relying on vagal stimulation alone.
Want the full science on how the vagus nerve influences pain, inflammation, and autonomic symptoms? Get My Vagus Nerve & Me eBook for a comprehensive guide to vagal function and evidence-based approaches to stimulation.




